Navigation Links
Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Remissions in Patients with Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Date:6/16/2011

SEATTLE, June 17, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced the publication of results posted in the online journal of Cancer of a Phase I-II study that evaluated the safety and efficacy of pixantrone when used in combination with fludarabine, dexamethasone and rituximab ("FPD-R") replacing mitoxantrone in the standard FND-R regimen with FPD-R among 28 patients with relapsed or refractory indolent non-Hodgkin's lymphoma ("INHL").

The Phase I-II study results showed that the FPD-R regimen was highly active in patients with relapsed or refractory INHL and produced complete responses ("CR") in 63% of patients with an overall response rate ("ORR") of 89%. Responses were long lasting for a median of 23 months with the longest responding patient in remission longer than 40 months, with an estimated 92% survival rate at three years. The primary side effects were hematologic with 89% of patients developing grade 3-4 neutropenia, which was managed with growth factor administration. No patient developed congestive heart failure with no grade 3-4 cardiac side effects observed. The authors concluded the FPD-R regimen was well-tolerated and highly active in patients with relapsed or refractory INHL.

"This study further adds to the evidence of substantial anti-tumor activity for pixantrone in late stage lymphoid malignancies," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "Of interest, of the 14 patients who were treated at M.D. Anderson Cancer Center, six who obtained a complete remission and did not have a stem-cell transplant remain in complete remission 55 to 83 months after completing therapy. Seven went on to receive a stem-cell transplant and six remain in remission. The high and durable complete response rate in this study indicates that additional clinical trials in relapsed or refractory INHL are warranted."

The publication is available at

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
2. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
3. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
4. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
5. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
6. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
7. New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
8. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
9. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
10. FDA Sets Meeting Date in Early June to Discuss Re-submission of Pixantrone NDA for Accelerated Approval
11. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... -- (May 30, 2010) -- In a development that ... researchers from Rice University and the Technion-Israel Institute of ... quantities of one-atom-thick sheets of carbon called graphene. ... Nature Nanotechnology . When stacked together, graphene sheets ...
... ... a detailed “road map” defining all aspects of the future 110-acre Livermore Valley Open ... site planning, and real estate development planning, as well as maintenance and operations planning. ... San Francisco, ...
... May 28 BioSpace.com is putting the nation,s Middle-Atlantic region on ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading career Web site for the life sciences ... edition and highlighting multiple companies within Washington D.C. , Delaware , ...
Cached Biology Technology:Liquid method: pure graphene production 2Flad Architects Awarded Livermore Valley Open Campus Master Plan 2BioSpace Launches 10th Campaign Map for the Mid-Atlantic 2BioSpace Launches 10th Campaign Map for the Mid-Atlantic 3
(Date:11/11/2014)... Nov. 11, 2014  Forensicon, Inc., a ... pleased to announce the promotion of Yaniv Schiff ... Digital Forensics. In Schiff,s new role as Director, he ... of digital forensics examiners and provide leadership within the ... - http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/7/2014)... November 6, 2014 Leading Biometric companies ... mobile security revolutionizing online transactions.  Companies in focus today are: ... (NYSE: BABA ), Google Inc. (NASDAQ: ... Inc. (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: ... and NXTDW), a biometric authentication company focused on the growing ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... times stronger than steel, weighs one-sixth as much and can ... The answer is a carbon nanotube -- and a new ... nanomaterials snap when subjected to ultrasonic vibrations in a liquid. ... but not bend, does not hold at the micro- and ...
... The Philippines, scientists from 21 research institutions from Germany, ... several concerns on the future of the rice ecosystems ... the framework of the international project LEGATO ... arising from various aspects of global change. "Threats ...
... used metal complexes to modify peptide hormones. In the ... report for the first time on the three-dimensional structure ... have laid the molecular foundation for the development of ... of Chemistry and Biochemistry at the Ruhr-University. The team ...
Cached Biology News:Tiny bubbles snap carbon nanotubes like twigs 2Tiny bubbles snap carbon nanotubes like twigs 3Sustainability of rice landscapes in South East Asia threatened 2A new avenue to better medicines: Metal-peptide complexes 2
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
Strip Removal Tool 25/Box...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
... Lambda Protein Phosphatase ... Mn2+-dependent protein phosphatase with ... threonine and tyrosine residues. ... amino-acid product of the ...
Biology Products: